Xcout IntelValneva SE competitors & alternatives
The 12 closest competitors and alternatives to Valneva SE among biotechnology companies — ranked by similarity to what Valneva SE actually does, not by market-cap band.
Subscribe to see Valneva SE’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Valneva SE
Valneva SE is a specialty vaccine company registered in Saint-Herblain, France, developing, producing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States.
Valneva SE at a glance
Valneva SE is a biotechnology company headquartered in Saint-Herblain, France. It is publicly listed (VALN) with a market capitalisation of $539.5M. Xcout tracks 18 named people at Valneva SE, including Thomas Lingelbach (President, Chief Executive Officer & Director). Xcout recorded 3 job postings from Valneva SE in the last 90 days.
Valneva SE leadership
- Thomas LingelbachPresident, Chief Executive Officer & Director
- Vincent DequenneChief Operating Officer
- Peter BuhlerChief Financial Officer
- Peter BühlerChief Financial Officer
- Juan-Carlos JaramilloChief Medical Officer
- Dipal PatelChief Commercial Officer
12 more named people on record for Valneva SE, with roles, board committees and tenure — see the full roster →
Hiring at Valneva SE
Xcout recorded 3 job postings from Valneva SE in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Valneva SE's hiring signals →
Top 12 Valneva SE competitors
Ranked by semantic similarity — how close each company is to Valneva SE by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Marinomed Biotech AG is an Austrian, science-driven biotech company headquartered in Korneuburg, Austria. The company is listed on the stock exchange.
Biotech
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
Similar biotechnology company
MalarVx, Inc. is a clinical-stage biopharmaceutical vaccine company located in Seattle, Washington, founded to develop innovative vaccines addressing global infectious diseases.
Biotech
Bavarian Nordic A/S is a fully integrated biotechnology company focused on the research, development, and manufacturing of life-saving vaccines. The company serves healthcare professionals, patients, and global markets by delivering innovative vaccine products and solutions.
Similar biotechnology company
Icosavax, Inc. is a Seattle, Washington-based clinical-stage biopharmaceutical company specializing in developing novel vaccines utilizing virus-like particle technology.
Similar biotechnology company
Hookipa Pharma Inc. is a clinical-stage biotechnology company developing immunotherapies and vaccines based on arenavirus vectors, designed to stimulate targeted T-cell and antibody responses. Its programs have focused on cancer and infectious diseases, serving patients through potential therapeutic and preventive treatments.
Biotech
Debiopharm is an independent biopharmaceutical company based in Switzerland that develops treatments for oncology and infectious diseases. The company focuses on drug development, drug manufacturing, and strategic investments in digital health and smart data start-ups.
Similar biotechnology company
Affinivax, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that pioneered a novel class of multiplex vaccine technologies.
Similar biotechnology company
Vaxxas is a clinical-stage biotechnology company headquartered in Brisbane, Australia. It is commercializing a novel vaccination technology designed to enhance the performance of existing and next-generation vaccines, and opened a biomedical manufacturing facility in Brisbane in June 2023.
Biotech
OSE Immunotherapeutics is a clinical-stage biotechnology company that develops innovative immunotherapies for immune activation and regulation in immuno-oncology and immuno-inflammation. The company utilizes proprietary research platforms and a portfolio of clinical-stage assets to provide therapeutic options for patients.
Similar biotechnology company
LimmaTech Biologics is a Swiss clinical-stage biotechnology company developing vaccines against bacterial infections, including drug-resistant pathogens. Its work includes conjugate vaccine candidates for Shigella and other diseases, serving pharmaceutical partners and ultimately patients at risk of serious bacterial infections.
Biotech
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Valneva SE and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Valneva SEand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →